Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
Journal: European journal of haematology
Published: November 14, 2022
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.
Journal: Leukemia & lymphoma
Published: May 13, 2022
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
Journal: Leukemia & lymphoma
Published: February 09, 2021
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Journal: Blood cancer journal
Published: September 18, 2020
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
Journal: Journal of geriatric oncology
Published: September 08, 2020
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Journal: Blood
Published: June 08, 2020
Clinician attitudes and practices toward measurable residual disease in multiple myeloma.
Journal: British journal of haematology
Published: June 08, 2020
Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 05, 2020
Last Updated: 09/26/2026